The effectiveness of lamivudine in preventing hepatitis B viral reactivation in rituximab-containing regimen for lymphoma

Annals of Hematology

Volumn 87, Issue 6, 2008, Pages 481-485

  He, Yi Fu ^a   Li, Yu Hong ^a   Wang, Feng Hua ^a   Jiang, Wen Qi ^a   Xu, Rui Hua ^a   Sun, Xiao Fei ^a   Xia, Zhong Jun ^a   Huang, Hui Qiang ^a   Lin, Tong Yu ^a   Zhang, Li ^a   Bao, Shi Ping ^a   He, You Jian ^a   Guan, Zhong Zhen ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Chemotherapy; Hepatitis B virus; Lamivudine; Non Hodgkin's lymphoma; Rituximab

Indexed keywords

ANTINEOPLASTIC AGENT; BILIRUBIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; LAMIVUDINE; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BILIRUBIN BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLICULAR LYMPHOMA; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HYPERBILIRUBINEMIA; INCIDENCE; INFECTION PREVENTION; LARGE CELL LYMPHOMA; MALE; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THERAPY DELAY; TOXIC HEPATITIS; TREATMENT OUTCOME; VIRUS CARRIER; VIRUS REACTIVATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; HEPATITIS B; HUMANS; LAMIVUDINE; LYMPHOMA; MALE; MIDDLE AGED; RECURRENCE; SALVAGE THERAPY; VIRUS ACTIVATION;

EID: 42549095725     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-008-0454-3     Document Type: Article

References (32)

1. Sun Z, Ming L, Zhu X, Lu J (2002) Prevention and control of hepatitis B in China. J Med Virol 67:447-450
2. Nakamura Y, Motokura T, Fujita A, Yamashita T, Ogata E (1996) Severe hepatitis related to chemotherapy in hepatitis B carriers with hematological malignancies. Cancer 78:2210-2215
3. Lau JY, Lai CL, Lin HJ, Lok AS, Liang RH, Wu PC et al (1989) Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lymphoma patients. Q J Med 73:911-917
4. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D (1991) Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100:182-188
5. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS et al (2000) Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. J Med Virol 62:299-307
6. Kumagai K, Takagi T, Nakamura S, Sawada U, Kura Y, Kodama F et al (1997) Hepatitis B virus carriers in the treatment of malignant lymphoma: An epidemiological study in Japan. Ann Oncol 8(suppl 1):107-109
7. Liang RH, Lok AS, Lai CL, Chan TK, Todd D, Chiu EK (1990) Hepatitis B infection in patients with lymphomas. Hematol Oncol 8:261-270
8. Liang R, Lau GK, Kwong YL (1999) Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carriers: A review of the problem. J Clin Oncol 17:394-398
9. Li YH, He YF, Jiang WQ, Wang FH, Lin XB, Zhang L et al (2006) Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 106:1320-1325
10. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242
11. van der Kolk LE, Baars JW, Prins MH, van Oers MH et al (2002) Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood 100:2257-2259
12. Suzan F, Ammor M, Ribrag V (2001) Fatal reactivation of cytomegalovirus infection after use of rituximab for a post-transplantation lymphoproliferative disorder. N Engl J Med 345:1000
13. Goldberg SL, Pecora AL, Alter RS, Kroll MS, Rowley SD, Waintraub SE et al (2002) Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 99:1486-1488
14. Bermudez A, Marco F, Conde E, Mazo E, Recio M, Zubizarreta A (2000) Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma. Haematologica 85:894-895
15. Ng HJ, Lim LC (2001) Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: Case report. Ann Hematol 80:549-552
16. Tsutsumi Y, Kawamura T, Saitoh S, Yamada M, Obara S, Miura TM et al (2004) Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: Necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma 45:627-629
17. Sera T, Hiasa Y, Michitaka K, Konishi I, Matsuura K, Tokumoto Y (2006) Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med 45:721-724
18. Dervite I, Hober D, Morel P (2001) Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 344:68-69
19. Skrabs C, Muller C, Agis H, Mannhalter C, Jager U (2002) Treatment of HBV carrying lymphoma patients with rituximab and CHOP: A diagnostic and therapeutic challenge. Leukemia 16:1884-1886
20. Niscola P, Del Principe MI, Maurillo L, Venditti A, Buccisano F, Piccioni D et al (2005) Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy. Leukemia 19:1840-1841
21. Tsutsumi Y, Tanaka J, Kawamura T, Miura T, Kanamori H, Obara S et al (2004) Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma. Ann Hematol 83:58-60
22. Yeo W, Chan PK, Chan HL, Mo FK, Johnson PJ (2001) Hepatitis B virus reactivation during cytotoxic chemotherapy-enhanced viral replication precedes overt hepatitis. J Med Virol 65:473-477
23. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10
24. Tsutsumi Y, Kanamori H, Mori A, Tanaka J, Asaka M, Imamura M, Masauzi N (2005) Reactivation of hepatitis B virus with rituximab. Expert Opin Drug Saf 4:599-608
25. Mimidis K, Tsatalas C, Margaritis D, Martinis G, Spanoudakis E, Kotsiou S et al (2002) Efficacy of lamivudine in patients with hematologic malignancies receiving chemotherapy and precore mutant chronic active hepatitis B. Acta Haematol 107:49-51
26. Hamaki T, Kami M, Kusumi E, Ueyama J, Miyakoshi S, Morinaga S, Mutou Y (2001) Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximab. Am J Hematol 68:292-294
27. Al-Taie OH, Mörk H, Gassel AM, Wilhelm M, Weissbrich B, Scheurlen M (1999) Prevention of hepatitis B flare-up during chemotherapy using lamivudine: Case report and review of the literature. Ann Hematol 78:247-249
28. Kami M, Hamaki T, Murashige N, Kishi Y, Kusumi E, Yuji K et al (2003) Safety of rituximab in lymphoma patients with hepatitis B or hepatitis C virus infection. Hematol J 4:159-162
29. Dai MS, Chao TY, Kao WY, Shyu RY, Liu TM (2004) Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 83:769-774
30. Perceau G, Diris N, Estines O, Derancourt C, Lévy S, Bernard P (2006) Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol 155:1053-1056
31. Hui CK, Cheung WW, Au WY, Lie AK, Zhang HY, Yueng YH et al (2005) Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with hematological malignancy on completion of cytotoxic chemotherapy. Gut 54:1597-1603
32. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ (1996) Selection of mutation in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 24:711-713